Mutual of America Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.62M Sell
109,603
-5,991
-5% -$333K 0.06% 337
2026
Q1
$6.72M Sell
115,594
-494
-0.4% -$22.8K 0.08% 307
2025
Q4
$5.2M Buy
116,088
+21,153
+22% +$888K 0.05% 421
2025
Q3
$3.81M Sell
94,935
-633
-0.7% -$22.3K 0.04% 542
2025
Q2
$2.99M Buy
95,568
+46,805
+96% +$1.53M 0.03% 651
2025
Q1
$1.64M Buy
+48,763
New +$1.85M 0.02% 892

Other funds holding XENE

Mutual of America Capital Management's XENE Position: Q2 2026 in Review

Mutual of America Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 5.2% in Q2 2026, selling an estimated $333K and leaving 109,603 shares worth $6.62M. The position accounts for 0.06% of the portfolio, ranked #337.

Mutual of America Capital Management first reported a position in XENE in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.72M in Q1 2026. 173 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Mutual of America Capital Management held 109,603 shares of Xenon Pharmaceuticals worth $6.62M as of Q2 2026.
  • Mutual of America Capital Management sold 5,991 Xenon Pharmaceuticals shares in Q2 2026, an estimated $333K.
  • Xenon Pharmaceuticals made up 0.06% of Mutual of America Capital Management's portfolio in Q2 2026, its #337 holding.
  • Mutual of America Capital Management first reported a position in Xenon Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Mutual of America Capital Management's Xenon Pharmaceuticals position peaked at $6.72M in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Mutual of America Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.